Virtus ETF Advisers’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-3,857
| Closed | -$61.1K | – | 485 |
|
|
2024
Q4 | $61.1K | Buy |
3,857
+1,998
| +107% | +$31.6K | 0.02% | 446 |
|
|
2024
Q3 | $108K | Buy |
1,859
+30
| +2% | +$1.74K | 0.05% | 365 |
|
|
2024
Q2 | $83.6K | Sell |
1,829
-738
| -29% | -$33.7K | 0.04% | 386 |
|
|
2024
Q1 | $170K | Sell |
2,567
-176
| -6% | -$11.7K | 0.09% | 305 |
|
|
2023
Q4 | $109K | Buy |
2,743
+182
| +7% | +$7.24K | 0.07% | 332 |
|
|
2023
Q3 | $81.6K | Sell |
2,561
-257
| -9% | -$8.19K | 0.05% | 357 |
|
|
2023
Q2 | $113K | Buy |
2,818
+801
| +40% | +$32.2K | 0.07% | 336 |
|
|
2023
Q1 | $86.1K | Sell |
2,017
-771
| -28% | -$32.9K | 0.05% | 373 |
|
|
2022
Q4 | $134K | Sell |
2,788
-1,037
| -27% | -$49.8K | 0.07% | 382 |
|
|
2022
Q3 | $144K | Buy |
3,825
+32
| +0.8% | +$1.21K | 0.06% | 359 |
|
|
2022
Q2 | $105K | Buy |
3,793
+568
| +18% | +$15.7K | 0.04% | 420 |
|
|
2022
Q1 | $175K | Sell |
3,225
-191
| -6% | -$10.4K | 0.08% | 208 |
|
|
2021
Q4 | $200K | Sell |
3,416
-600
| -15% | -$35.1K | 0.08% | 209 |
|
|
2021
Q3 | $159K | Sell |
4,016
-213
| -5% | -$8.43K | 0.07% | 328 |
|
|
2021
Q2 | $180K | Buy |
4,229
+394
| +10% | +$16.8K | 0.07% | 386 |
|
|
2021
Q1 | $236K | Buy |
3,835
+77
| +2% | +$4.74K | 0.1% | 299 |
|
|
2020
Q4 | $265K | Buy |
+3,758
| New | +$265K | 0.11% | 290 |
|